Cancer patients can respond very differently to the same treatment, while current testing may not reliably identify the therapy most likely to work for each tumor.
R&D Focus
Liquid biopsy and molecular residual disease monitoring
Innovative Solution
METHYS Dx develops panels of methylation markers to characterize circulating tumor DNA (ctDNA) within liquid biopsies. The company focuses on personalized medicine in oncology, providing non-invasive tests for cancer patient monitoring.
Investment Funding
Revenue
$1M to $10M
About
METHYS Dx develops panels of methylation markers to characterize circulating tumor DNA (ctDNA) within liquid biopsies. The company focuses on personalized medicine in oncology, providing non-invasive tests for cancer patient monitoring. These innovative liquid biopsy tests help in the early detection and monitoring of cancer, offering a less invasive alternative to traditional biopsy methods.
Something missing or incorrect on this page? Help us enrich this information
